Head-to-head evidence
LY03017 vs Pimavanserin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanisms: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · 5-HT2A/2C receptor · full Parkinson's Disease pipeline
LY03017
Developed by Luye Pharma Group
NCT06388551 · Phase 1 · status unknown
This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known.
Pimavanserin · Nuplazid
Marketed by Acadia Pharmaceuticals
NCT00477672 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 298 participants and a clinical symptom-scale primary endpoint. The primary comparison was not statistically significant: the confidence intervals for both pimavanserin doses versus placebo included no difference, so the trial provides well-controlled but negative or inconclusive evidence of benefit.
Next expected readout: June 2027 · NCT06455293 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03017's landscape · Pimavanserin's landscape